# CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

> **NCT03032406** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 53 (actual)

## Conditions studied

- Breast Cancer Stage IIB

## Interventions

- **DRUG:** Hydroxychloroquine
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT03032406
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-01-23
- **Primary completion:** 2022-05-17
- **Final completion:** 2026-01-01
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2025-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03032406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03032406, "CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03032406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*